Overview
Sparing and Restoring the Gut Microbiota: A Faculty Review of Recent Abstracts and Literature in C. difficile
A video brief from Dr. Paul Feuerstadt
Click the"View Activity" button to view this activity.
View ActivityActivity already occured. CME/CE is no longer available for this activity
Don’t have time to sift through all the literature and data recently published on C. difficile? Dr. Paul Feuerstadt provides a concise and practical review of the literature including the changing epidemiology, and the safety and efficacy of fecal microbiota transplantation.
This activity is intended for gastroenterologists, primary care physicians, and other clinicians who care for patients at risk of C. difficile infection
Recurrent episodes of C. difficile continue to pose a significant burden on patients, clinicians, and the healthcare system. The management of recurrent and refractory C. difficile is complex and challenging. This activity will review the role of the gut microbiome in C. difficile infection, discuss evidence-based guidelines for treatment and prevention of recurrent infection, and describe emerging restoration approaches that reduce complications and improve clinical outcomes.
- Explain the role of the gut microbiome in relationship to C. difficile infection and approaches to restoration for prevention of recurrent infection
- Discuss the changing epidemiology of community and healthcare-associated C. difficile infection
- Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by educational grants from Ferring Pharmaceuticals Inc., and Merck & Company.
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Paul Feuerstadt, MD, FACG, AGAF
Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Roche Diagnostics
Speakers' Bureau: Merck and Company
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Karen Catino at kcatino@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.